Believe me when I say nobody wants PharmaCyte's Cell-in-a-Box® technology to benefit patients more than I - patients suffering from pancreatic cancer, breast cancer, malignant ascites, brain cancer and not least of all diabetes. My spouse is an insulin-dependent diabetic. Trust me, I want/need this technology to get to market as much as anyone. I've done extensive DD on the CiaB/Melligen cell combo for diabetes - there is nothing better to treat diabetes.
However, as we all know, money talks and there isn't much we can do about that either way. Big pharma could very well buy the technology for non-compete purposes. Should that happen, at least PMCB investors benefit knowing we tried and did our best. No lack of effort here by anyone.
Patient and positive here as well.
#FFO
News 
Market Data 
Discover 
